Kanagawa Cancer Center

Running trials

• Recruiting

  A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

  NCT07701941· Phase 1/2· Daiichi Sankyo· Source

• Recruiting

  A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC

  NCT07733180· Phase 2· BeOne Medicines· Source

• Recruiting

  A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer

  NCT07766018· Phase 2· Stemline Therapeutics, Inc.· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers

  NCT07769502· Phase 2· AbbVie· Source

• Recruiting

  Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

  NCT07872722· Phase 2· National Cancer Center, Japan· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer

  NCT07710885· Phase 3· Taiho Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

  NCT07549412· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

  NCT07623616· Phase 2· Kyowa Kirin Co., Ltd.· Source

• Recruiting

  A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

  NCT07405151· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  NCT07221149· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

  NCT07128199· Phase 3· Taiho Oncology, Inc.· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT07252232· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Recruiting

  A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

  NCT07218146· Phase 3· Zai Lab (Shanghai) Co., Ltd.· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

  NCT07166094· Phase 3· Genmab· Source

• Recruiting

  Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  NCT06899126· Phase 3· Daiichi Sankyo· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

  NCT07190248· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Pfizer· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Pfizer· Source

• Recruiting

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· Phase 3· Pfizer· Source

• Recruiting

  Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  NCT06765109· Phase 3· Nuvalent Inc.· Source

• Recruiting

  A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

  NCT06997497· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  NCT06966700· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  NCT06881784· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

  NCT06801834· Phase 3· Gilead Sciences· Source

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

  NCT06644781· Phase 3· Daiichi Sankyo· Source

• Recruiting

  A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

  NCT06841354· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

  NCT06742996· Phase 3· BeOne Medicines· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Daiichi Sankyo· Source

• Recruiting

  Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

  NCT06712355· Phase 3· BioNTech SE· Source

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Pfizer· Source

• Active, not recruiting

  Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

  NCT06501625· Phase 1/2· Institut de Recherches Internationales Servier· Source

• Active, not recruiting

  Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

  NCT06635824· Phase 3· Genmab· Source

• Recruiting

  A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  NCT06623422· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT06625320· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  NCT06561386· Phase 3· Bristol-Myers Squibb· Source

Showing 50 of 147.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer28 recruiting
• Colorectal cancer11 recruiting
• Gastric and oesophageal cancer9 recruiting
• Metastatic breast cancer6 recruiting
• Pancreatic cancer6 recruiting
• Childhood cancers4 recruiting
• Liver and biliary tract cancer3 recruiting
• Triple-negative breast cancer3 recruiting
• Cervical cancer2 recruiting
• Endometrial cancer2 recruiting
• Head and neck cancer2 recruiting
• Melanoma2 recruiting
• Multiple myeloma2 recruiting
• Ovarian cancer2 recruiting
• Prostate cancer2 recruiting
• Sarcoma2 recruiting
• Thyroid cancer2 recruiting
• Acute myeloid leukaemia1 recruiting
• Bladder cancer1 recruiting
• Brain metastases1 recruiting
• Mantle cell lymphoma1 recruiting
• Neuroendocrine tumours1 recruiting

Closed trials

• Recruiting

  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  NCT06282575· Phase 3· Jazz Pharmaceuticals· Source

• Completed

  A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

  NCT06188559· Phase 2· Eisai Inc.· Source

• Completed

  A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

  NCT05867121· Phase 1· Genentech, Inc.· Source

• Completed

  Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

  NCT05882734· Phase 1/2· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

  NCT05862285· Phase 3· Hoffmann-La Roche· Source

• Completed

  Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

  NCT05512377· Phase 2· Boehringer Ingelheim· Source

• Completed

  Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

  NCT05546476· Phase 2· Pfizer· Source

• Completed

  Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

  NCT05153239· Phase 3· PharmaMar· Source

• Completed

  Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

  NCT05258279· Phase 2· Juntendo University· Source

• Completed

  Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

  NCT05298423· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

  NCT05241873· Phase 1· Blueprint Medicines Corporation· Source

• Completed

  A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

  NCT05002127· Phase 2/3· ALX Oncology Inc.· Source

• Completed

  ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

  NCT06570031· Phase 1· Ono Pharmaceutical Co., Ltd.· Source

• Completed

  Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer

  NCT06525246· Phase 1· Ono Pharmaceutical Co., Ltd.· Source

• Terminated

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).

  NCT04949256· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

  NCT04862780· Phase 1· Blueprint Medicines Corporation· Source

• Completed

  An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer

  NCT06542731· Phase 1· Ono Pharmaceutical Co., Ltd.· Source

• Completed

  Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia

  NCT04813263· AbbVie· Source

• Completed

  Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

  NCT04776148· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

  NCT04744831· Phase 2· Daiichi Sankyo· Source

• Completed

  An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer

  NCT06538207· Phase 1· Ono Pharmaceutical Co., Ltd.· Source

• Terminated

  Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

  NCT04093362· Phase 3· Taiho Oncology, Inc.· Source

• Completed

  Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

  NCT04662710· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

  NCT04543617· Phase 3· Hoffmann-La Roche· Source

• Completed

  Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection

  NCT04457297· Phase 3· National Cancer Center Hospital East· Source

• Completed

  Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

  NCT04210115· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

  NCT04172246· Phase 1/2· BeiGene· Source

• Completed

  TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

  NCT04129502· Phase 3· Takeda· Source

• Completed

  A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

  NCT04102098· Phase 3· Hoffmann-La Roche· Source

• Completed

  Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

  NCT04003636· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

  NCT03940703· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

  NCT03976362· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

  NCT03976323· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

  NCT03829332· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

  NCT03535740· Phase 2· Ariad Pharmaceuticals· Source

• Completed

  Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

  NCT03713593· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

  NCT03777657· Phase 3· BeiGene· Source

• Completed

  A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

  NCT03783442· Phase 3· BeiGene· Source

• Completed

  Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

  NCT03675737· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

  NCT03615326· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

  NCT03529110· Phase 3· Daiichi Sankyo· Source

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Daiichi Sankyo· Source

• Terminated

  A Study of PF-06873600 in People With Cancer

  NCT03519178· Phase 1/2· Pfizer· Source

• Completed

  A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

  NCT03412773· Phase 3· BeiGene· Source

• Completed

  Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

  NCT03358472· Phase 3· Incyte Corporation· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

  NCT03221426· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

  NCT03248492· Phase 2· Daiichi Sankyo· Source

• Completed

  A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

  NCT03193190· Phase 1/2· Hoffmann-La Roche· Source

• Completed

  Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

  NCT02486718· Phase 3· Hoffmann-La Roche· Source

Showing 50 of 52.

Conditions

Diseases this institution publishes on or runs trials for.

• Gastric and oesophageal cancer51 works · 24 trials
• Pancreatic cancer36 works · 17 trials
• Metastatic breast cancer17 works · 26 trials